EUVIMEDEUVIMED entdecken
Systematische ÜbersichtMetaanalyseLeserbriefOpen Access · CC BY-NC-ND 4.0

Elevation of creatine phosphokinase in moderate-to-severe atopic dermatitis is associated with the use of JAK inhibitors but not dupilumab: A systematic review and meta-analysis

Daud Manzar, Emmanuel Suntres, Nikhil Nair, Yash Patel, Mohannad Abu-Hilal

Journal of the American Academy of Dermatology · 2024

DOI: 10.1016/j.jaad.2024.03.027 ↗

Kurz gefasst

Systematische Übersicht in der Zeitschrift Journal of the American Academy of Dermatology, 2024. Verfasst von Daud Manzar und 4 weiteren Autor:innen. Beteiligte Einrichtung: Michael G. DeGroote School of Medicine, McMaster University, Hamilton, Ontario, Canada. Hauptthemen laut MEDLINE: Dermatitis, Atopic, Antibodies, Monoclonal, Humanized, Janus Kinase Inhibitors, Severity of Illness Index. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 5 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

To the Editor: Recently, many novel advanced systemic therapies have been approved for the treatment of moderate-to-severe atopic dermatitis (AD), including interleukin (IL)-4/IL-13 inhibitors (dupilumab), IL-13 inhibitors (tralokinumab), and selective Janus kinase (JAK)-1 inhibitors (abrocitinib and upadacitinib). There is uncertainty regarding the potential elevation of creatine phosphokinase (CPK) levels with these therapies, and whether this increase is linked to clinically significant outcomes, such as rhabdomyolysis and renal failure.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Dermatitis, AtopicAntibodies, Monoclonal, HumanizedJanus Kinase InhibitorsSeverity of Illness IndexCreatine KinaseHumansNitrilesPyrimidinesPiperidines

Stichwörter der Autor:innen

JAK-inhibitorabrocitinibatopic dermatitiscreatine phosphokinasedupilumabupadacitinib

Substanzen

Antibodies, Monoclonal, HumanizeddupilumabJanus Kinase InhibitorsCreatine KinaseNitrilesPyrimidinestofacitinibPiperidines

Autor:innen und Institutionen

  • Michael G. DeGroote School of Medicine, McMaster University, Hamilton, Ontario, Canada.
  • Temerty Faculty of Medicine, University of Toronto, Toronto, Ontario, Canada.
  • Michael G. DeGroote School of Medicine, McMaster University, Hamilton, Ontario, Canada; Division of Dermatology, McMaster University, Hamilton, Ontario, Canada. Electronic address: abuhilm@mcmaster.ca.

Zitieren

APA

Manzar, D., Suntres, E., Nair, N., Patel, Y., & Abu-Hilal, M. (2024). Elevation of creatine phosphokinase in moderate-to-severe atopic dermatitis is associated with the use of JAK inhibitors but not dupilumab: A systematic review and meta-analysis. Journal of the American Academy of Dermatology. https://doi.org/10.1016/j.jaad.2024.03.027

Vancouver

Manzar D, Suntres E, Nair N, Patel Y, Abu-Hilal M. Elevation of creatine phosphokinase in moderate-to-severe atopic dermatitis is associated with the use of JAK inhibitors but not dupilumab: A systematic review and meta-analysis. Journal of the American Academy of Dermatology. 2024. doi:10.1016/j.jaad.2024.03.027

BibTeX
@article{Manzar2024,
  author = {Manzar, Daud and Suntres, Emmanuel and Nair, Nikhil and Patel, Yash and Abu-Hilal, Mohannad},
  title = {Elevation of creatine phosphokinase in moderate-to-severe atopic dermatitis is associated with the use of JAK inhibitors but not dupilumab: A systematic review and meta-analysis},
  journal = {Journal of the American Academy of Dermatology},
  year = {2024},
  doi = {10.1016/j.jaad.2024.03.027}
}
Kostenlos starten →